CTRI/2024/05/066837尚未招募3 期
Multimodal Management of stage II and III extraocular retinoblastoma : An Interventional pilot study - NI
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Those fulfilling the criteria for IRSS stage II and III of extraocular retinoblastoma defined previously will be included in the study.
排除标准
- •Pre-existing renal disease
- •Pre-existing Hearing impairment
- •Relapsed extraocular retinoblastoma
研究者
相似试验
进行中（未招募）
3 期
The Multi-Arm GlioblastoMa Australasia (MAGMA) Trial is a platform trial that will assess a number of options in standard of care for the management of glioblastoma. Initial questions of interest are: QUESTION 1 whether or not to give a cycle of temozolomide prior to chemoradiotherapy and QUESTION 2: whether to give 6 cycles of temozolomide after chemoradiotherapy, or continue monthly treatment until disease progressioCancer - BrainGlioblastomaACTRN12620000048987HMRC Clinical Trials Centre (CTC), University of Sydney338
已完成
不适用
PHASE II / III, OPEN AND MULTICENTRIC CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFECTIVENESS OF FACTOR I SIMILAR GROWTH TO INSULIN / PROTEIN 3 OF UNION TO FACTOR I OF GROWTH SIMILAR TO INSULIN (RHIGF-I / RHIGFBP-3 ) ADMINISTERED FOR 12 MONTHS TO CHILDREN AND ADOLESCENTS WITH SYNDROME OF INSENSIBILITY TO GROWTH HORMONE (GHIS) LIKE LARON SYNDROMEPER-061-04INSMED INCORPORATED,
进行中（未招募）
1 期
Evaluation of a combined anticancer treatment consisting of pre- and postoperative intravenous polychemotherapy, extensive tumor surgery and heated intraabdominal chemotherapy in patients with peritoneal spread of colonic cancerSynchronous or metachronous peritoneal carcinomatosis (PC) from appendiceal or colorectal cancerMedDRA version: 17.1Level: LLTClassification code 10068069Term: Peritoneal carcinomatosisSystem Organ Class: 100000004864EUCTR2009-014040-11-DEniversity of Regensburg60
Unknown
2 期
PanACEA-MAMS-TB-01TuberculosisPACTR201205000383208Prof. Karl Walter Jauch, Medical Director, Klinikum of the Universtiy of Munich372
招募中
1 期
A phase 3b, interventional, adaptive, clinical trial to evaluate the efficacy and safety of tralokinumab 300 mg every second week monotherapy compared with placebo in subjects with moderate-to-severe atopic hand eczema who are candidates for systemic therapy (ADHAND)Atopic dermatitis and moderate-to severe atopic hand eczemaMedDRA version: 21.1Level: LLTClassification code: 10003639Term: Atopic dermatitis Class: 10040785MedDRA version: 21.1Level: LLTClassification code: 10003641Term: Atopic eczema Class: 10040785CTIS2022-502653-34-01EO PHARMA A/S402